Rapid Readouts

1 expert is featured in this series

Nikhil I. Khushalani, MD, of Moffitt Cancer Center in Tampa, Florida, reviews updated efficacy and safety results from the pivotal open-label study of cosibelimab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic cutaneous squamous cell carcinoma, with a median follow-up of at least 2.5 years, as presented at the 2026 ESMO Congress.

Elizabeth K. Lee, MD, of Dana-Farber Cancer Institute in Boston, Massachusetts, reviews the first efficacy and safety results from the phase 2 cohort of the RAINFOL-01 study of rinatabart sesutecan, a folate receptor alpha (FRα)-directed antibody-drug conjugate, in patients with platinum-resistant ovarian cancer, as presented at the 2026 International Gynecologic Cancer Society Annual Global Meeting.

This Rapid Readout reviews clinical trials showing that sunvozertinib is an effective and manageable targeted therapy for non-small cell lung cancer patients with specific EGFR mutations, demonstrating strong antitumor activity after platinum-based chemotherapy and improved progression-free survival and response rates over standard chemotherapy as a first-line treatment.

The Phase 3 PAPILLON study evaluated first-line amivantamab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer with EGFR Exon 20 insertion mutations. The amivantamab-chemotherapy group achieved the longest median overall survival reported to date in this population compared to chemotherapy alone. After adjusting for the high rate of crossover to second-line amivantamab among patients initially assigned to chemotherapy, the combination treatment demonstrated a statistically significant overall survival benefit.

Roy S. Herbst, MD, PhD, reviews the exploratory 8-year overall survival landmark update from the phase 3 ADAURA trial of adjuvant osimertinib versus placebo in patients with resected EGFR-mutated stage IB to IIIA non-small cell lung cancer, presented at the 2026 World Conference on Lung Cancer.

The EXCALIBER-RRMM clinical trial evaluated a combination therapy of iberdomide, daratumumab, and dexamethasone against daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. The trial demonstrated that adding the cereblon E3 ligase modulator iberdomide significantly improved minimal residual disease-negative complete response rates across diverse patient subgroups while maintaining a predictable and manageable safety profile. Based on these outcomes, the regulatory authority granted accelerated approval for this treatment combination as a new standard of care for patients experiencing early relapse.

Julia Rotow, MD, of Dana-Farber Cancer Institute, reviews primary results of the phase 3 DESTINY-Lung04 trial showing first-line trastuzumab deruxtecan improved progression-free survival and response rate compared with pembrolizumab plus platinum chemotherapy and pemetrexed in patients with metastatic HER2-mutant non-small cell lung cancer.

1 expert is featured in this series.

Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, presents updated overall survival and safety findings from Stage 1 of the phase 3 PRESERVE-003 trial of gotistobart vs docetaxel in patients with metastatic squamous non–small cell lung cancer whose disease progressed after chemotherapy and PD-1 or PD-L1 inhibitor therapy.

1 expert is featured in this series.

Dr. Neeta Somaiah discusses PEAK trial results showing that adding bezuclastinib to sunitinib nearly doubled median progression-free survival (16.5 vs 9.2 months) and improved overall response rate versus sunitinib alone in second-line, imatinib-resistant gastrointestinal stromal tumors.

1 expert is featured in this series.

Amir T. Fathi, MD, presents a multicenter retrospective cohort study demonstrating that intensive chemotherapy plus quizartinib was associated with superior 1-year overall survival (93% vs 78%; adjusted HR, 0.19) and event-free survival compared with intensive chemotherapy plus midostaurin in patients with newly diagnosed FLT3-ITD–mutated acute myeloid leukemia.

1 expert is featured in this series.

Charu Aggarwal, MD, MPH, discusses planned interim results from the phase 2b TRITON trial evaluating tremelimumab plus durvalumab and chemotherapy versus pembrolizumab plus chemotherapy in patients with previously untreated metastatic non–small cell lung cancer harboring STK11, KEAP1, and/or KRAS mutations.

1 expert is featured in this series.

This presentation shows that the next-generation BTK inhibitor zanubrutinib demonstrates increasingly durable long-term survival and progression-free benefits compared with ibrutinib and acalabrutinib in previously untreated chronic lymphocytic leukemia, supporting its use as a preferred frontline therapy when direct comparative trial data are unavailable.

1 expert is featured in this series.

Jiong Wu, MD, PhD, discusses phase 3 PANKU-Breast02 findings showing that izalontamab brengitecan improved progression-free and overall survival vs chemotherapy in patients with previously treated unresectable locally advanced or metastatic triple-negative breast cancer.